Abstracts tagged "Spondyloarthropathies"

Abstract Number: 1234 • ACR Convergence 2022
Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex
Lihi Eder¹ and Kangping Cui², ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
Background/Purpose: Musculoskeletal ultrasound (MSK-US) provides valuable information on disease phenotype in psoriatic arthritis (PsA). While age and sex are important determinants of health, limited information…
Abstract Number: 2114 • ACR Convergence 2022
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Iain B McInnes¹, Enrique R Soriano², Lai-shan Tam³, Natalie Shiff⁴, May Shawi⁵, Emmanouil Rampakakis⁶ and Jeffrey Curtis⁷, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³The Chinese University of Hong Kong, Hong Kong, China, ⁴Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷University of Alabama at Birmingham, Division of Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…
Abstract Number: 0491 • ACR Convergence 2021
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Lianne Gensler¹, Atul Deodhar², Désirée van der Heijde³, Denis Poddubnyy⁴, Alan Kivitz⁵, Maxime Dougados⁶, Natasha de Peyrecave⁷, Marga Oortgiesen⁸, Thomas Vaux⁹, Carmen Fleurinck⁷ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Xenofon Baraliakos¹, Roberto Ranza², Andrew Ostor³, Francesco Ciccia⁴, Laura Coates⁵, Simona Rednic⁶, Jessica Walsh⁷, Tianming Gao⁸, Apinya Lertratanakul⁸, In-Ho Song⁸, Fabiana Ganz⁸, Kevin Douglas⁸ and Atul Deodhar⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ³Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁴University of Campania Luigi Vanvitelli, Napoli, Italy, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸AbbVie Inc., North Chicago, IL, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
Abstract Number: 0575 • ACR Convergence 2021
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Olivier Fakih, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…
Abstract Number: 0642 • ACR Convergence 2021
Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics
Lihi Eder¹, Shadi Akhtari², Dana Jerome¹, Jacob Udell¹, Patrick Lawler¹, Paula Harvey³ and Bindee Kuriya⁴, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Cardio-metabolic abnormalities are common in patients with inflammatory arthritis (IA) but tend to be under-recognized and under-treated. We aimed to compare the prevalence and…
Abstract Number: 0749 • ACR Convergence 2021
Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial
Xenofon Baraliakos¹, Louis Bessette², Carlo Salvarani³, Naijun Chen⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, In-Ho Song⁴, Patrick Zueger⁶ and Philippe Goupille⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Laval University, Québec City, QC, Canada, ³Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Universita di Moderna e Reggio Emilia, Reggio Emilia, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷University hospital of Tours, Rheumatology department, Tours, France
Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease…
Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Claire Deakin¹, Geoffrey Littlejohn², Hedley Griffiths³, Tegan Smith⁴, Catherine OSullivan⁵ and Paul Bird⁶, ¹OPAL Rheumatology Ltd, Sydney, Australia, ²Monash University, Melbourne, Australia, ³Barwon Rheumatology Service, Geelong, Australia, ⁴OPAL Rheumatology Ltd, Kogarah, Australia, ⁵OPAL Rheumatology Ltd, Queenscliff, Australia, ⁶University of New South Wales, Sydney, Australia
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…
Abstract Number: 0905 • ACR Convergence 2021
Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
Denis Poddubnyy¹, Janis Vahldiek², Lisa Adams², Torsten Diekhoff², Fabian Proft², Mikhail Protopopov², Judith Rademacher², Valeria Rios Rodriguez², Murat Torgutalp², Stefan Niehues² and Keno Bressem², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Active inflammatory changes in sacroiliac joints (SIJ) compatible with axial spondyloarthritis - axSpA (first of all, subchondral bone marrow edema – BME / osteitis)…
Abstract Number: 0922 • ACR Convergence 2021
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Atul Deodhar¹, Maxime Dougados², Karl Gaffney³, Raj Sengupta⁴, Marina Magrey⁵, Natasha de Peyrecave⁶, Marga Oortgiesen⁷, Thomas Vaux⁸, Carmen Fleurinck⁶, Vanessa Taieb⁸, Christine de la Loge⁹ and Xenofon Baraliakos¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ³Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ⁴The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Slough, United Kingdom, ⁹PCOM Analytics, Avallon, France, Avallon, France, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Philip Robinson¹, Pedro Machado², Nigil Haroon³, Lianne Gensler⁴, John Reveille⁵, Vanessa Taieb⁶, Thomas Vaux⁶, Carmen Fleurinck⁷, Marga Oortgiesen⁸, Natasha de Peyrecave⁷ and Atul Deodhar⁹, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…
Abstract Number: 0250 • ACR Convergence 2021
Is There a Need for a New Classification Criteria in Juvenile Spondyloarthritis?
Maria Martha Katsicas¹, Maria Cecilia Bertinotti² and Maria Giselle Villarreal², ¹Hospital de Pediatria J.P Garrahan, Buenos Aires, Argentina, ²Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile SpA (JSpA) involve enthesitis related arthritis (ERA), juvenile psoriatic arthritis and undifferentiated arthritis (UA) according to the ILAR criteria. Two different patterns have…
Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay Von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Späthling-Mestekemper⁸, Christoph Kuhn⁹, Fabian Proft¹⁰, Denis Poddubnyy¹¹, Mathias Englbrecht¹² and Wolfgang Vorbrüggen¹³, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Rhein-Maas Klinikum, Wuerselen, Germany, ³Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁴Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁵Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ⁶rheumapraxis, Osnabrck, Germany, ⁷Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁸Rheumapraxis München, München, Germany, ⁹Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹²Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹³Verein zur Förderung der Rheumatologie e.V., Würselen, Germany
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Gino Chesini¹, Elizabeth Parrott¹, Lauren Fox¹, Jenna Beatty¹, Cassandra Effken¹, Na Yu¹, Florence Hosseini-Aslinia¹ and Megan Krause², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].